A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation.

The ETS-domain transcription factors divide into subfamilies based on protein similarities, DNA-binding sequences, and interaction with cofactors. They are regulated by extracellular clues and contribute to cellular processes, including proliferation and transformation. ETS genes are targeted through genomic rearrangements in oncogenesis. The PU.1/SPI1 gene is inactivated by point mutations in human myeloid malignancies. We identified a recurrent somatic mutation (Q226E) in PU.1/SPI1 in Waldenström macroglobulinemia, a B-cell lymphoproliferative disorder. It affects the DNA-binding affinity of the protein and allows the mutant protein to more frequently bind and activate promoter regions with respect to wild-type protein. Mutant SPI1 binding at promoters activates gene sets typically promoted by other ETS factors, resulting in enhanced proliferation and decreased terminal B-cell differentiation in model cell lines and primary samples. In summary, we describe oncogenic subversion of transcription factor function through subtle alteration of DNA binding leading to cellular proliferation and differentiation arrest. SIGNIFICANCE: The demonstration that a somatic point mutation tips the balance of genome-binding pattern provides a mechanistic paradigm for how missense mutations in transcription factor genes may be oncogenic in human tumors.This article is highlighted in the In This Issue feature, p. 681.

[1]  W. Shi,et al.  Environmental sensing by mature B cells is controlled by the transcription factors PU.1 and SpiB , 2017, Nature Communications.

[2]  Manolis Kellis,et al.  Chromatin-state discovery and genome annotation with ChromHMM , 2017, Nature Protocols.

[3]  D. Dunson,et al.  Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.

[4]  Aviad Tsherniak,et al.  Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. , 2017, Cancer discovery.

[5]  S. Miyano,et al.  Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia , 2017, Nature Genetics.

[6]  S. Nutt,et al.  Genome-Wide Identification of Target Genes for the Key B Cell Transcription Factor Ets1 , 2017, Front. Immunol..

[7]  P. Vyas,et al.  Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage , 2016, The Journal of experimental medicine.

[8]  Martin A. Nowak,et al.  Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.

[9]  G. Boucher,et al.  The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias , 2015, Nature Genetics.

[10]  K. Basso,et al.  Germinal centres and B cell lymphomagenesis , 2015, Nature Reviews Immunology.

[11]  R. DeKoter,et al.  Genome-wide comparison of PU.1 and Spi-B binding sites in a mouse B lymphoma cell line , 2015, BMC Genomics.

[12]  Wei Shi,et al.  The transcription factors IRF8 and PU.1 negatively regulate plasma cell differentiation , 2014, The Journal of experimental medicine.

[13]  C. Abreu-Goodger,et al.  The miR-155–PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation , 2014, The Journal of experimental medicine.

[14]  Paul Shinn,et al.  Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors , 2014, Proceedings of the National Academy of Sciences.

[15]  Satoru Miyano,et al.  Acquired initiating mutations in early hematopoietic cells of CLL patients. , 2014, Cancer discovery.

[16]  B. Beutler,et al.  Consequences of the recurrent MYD88L265P somatic mutation for B cell tolerance , 2014, The Journal of experimental medicine.

[17]  W. Chan,et al.  Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. , 2013, Blood.

[18]  S. Chevret,et al.  Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia , 2013, Haematologica.

[19]  L. Garrett-Sinha Review of Ets1 structure, function, and roles in immunity , 2013, Cellular and Molecular Life Sciences.

[20]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[21]  Emmanuel Barillot,et al.  Spi-1/PU.1 activates transcription through clustered DNA occupancy in erythroleukemia , 2012, Nucleic acids research.

[22]  Paul Shinn,et al.  Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.

[23]  P. Opolon,et al.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.

[24]  Peter C. Hollenhorst,et al.  Genomic and biochemical insights into the specificity of ETS transcription factors. , 2011, Annual review of biochemistry.

[25]  Joseph M. Connors,et al.  Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.

[26]  L. Garrett-Sinha,et al.  Regulation of Follicular B Cell Differentiation by the Related E26 Transformation-Specific Transcription Factors PU.1, Spi-B, and Spi-C , 2010, The Journal of Immunology.

[27]  Andrew R. Gehrke,et al.  Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo , 2010, The EMBO journal.

[28]  J. Crowley,et al.  International prognostic scoring system for Waldenstrom macroglobulinemia. , 2009, Blood.

[29]  A. Baruchel,et al.  Activating mutations in human acute megakaryoblastic leukemia. , 2008, Blood.

[30]  G. Gilkeson,et al.  The Transcription Factor Fli-1 Modulates Marginal Zone and Follicular B Cell Development in Mice1 , 2008, The Journal of Immunology.

[31]  Harinder Singh,et al.  Gene regulatory networks directing myeloid and lymphoid cell fates within the immune system. , 2008, Seminars in immunology.

[32]  L. Garrett-Sinha,et al.  Ets-1 Regulates Plasma Cell Differentiation by Interfering with the Activity of the Transcription Factor Blimp-1* , 2008, Journal of Biological Chemistry.

[33]  W. Leonard,et al.  The transcription factor GABP is a critical regulator of B lymphocyte development. , 2007, Immunity.

[34]  L. Staudt,et al.  Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphoma , 2007, The Journal of experimental medicine.

[35]  L. Staudt,et al.  A library of gene expression signatures to illuminate normal and pathological lymphoid biology , 2006, Immunological reviews.

[36]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[37]  S. Nutt,et al.  Oncogenes and Tumor Suppressors (795 articles) Plenary Papers (356 articles) , 2004 .

[38]  C. Foulds,et al.  Ras/Mitogen-Activated Protein Kinase Signaling Activates Ets-1 and Ets-2 by CBP/p300 Recruitment , 2004, Molecular and Cellular Biology.

[39]  J. Kutok,et al.  Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1 , 2004, Nature Genetics.

[40]  M. Dimopoulos,et al.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[41]  G. Blobel,et al.  Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 , 2002, Molecular and Cellular Biology.

[42]  A. Sharrocks The ETS-domain transcription factor family , 2001, Nature Reviews Molecular Cell Biology.

[43]  B. Graves,et al.  Phosphorylation represses Ets-1 DNA binding by reinforcing autoinhibition. , 2000, Genes & development.

[44]  A. Brass,et al.  Assembly requirements of PU.1–Pip (IRF‐4) activator complexes: inhibiting function in vivo using fused dimers , 1999, The EMBO journal.

[45]  F. Moreau-Gachelin,et al.  The Transcription Factor Spi-1/PU.1 Binds RNA and Interferes with the RNA-binding Protein p54(*) , 1996, The Journal of Biological Chemistry.

[46]  F. Moreau-Gachelin,et al.  DNA binding specificities of Spi-1/PU.1 and Spi-B transcription factors and identification of a Spi-1/Spi-B binding site in the c-fes/c-fps promoter. , 1995, Oncogene.

[47]  E. Scott,et al.  Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. , 1994, Science.

[48]  Razvan R. Popovici,et al.  Additional file 8 , 2010 .

[49]  M. Minden,et al.  Heterozygous PU.1 mutations are associated with acute myeloid leukemia. , 2002, Blood.

[50]  K. Nakayama,et al.  Transcription Factor PU.1 Represses and Activates Gene Expression in Early T Cells by Redirecting Partner Transcription Factor Binding , 2018, Immunity.